Project information

Rigorous scientific research of moxa TB treatment

To scientifically test and hopefully prove the findings we have been getting with our feasability studies in Uganda and South Africa in collaboration with the Deparytment of Pharmacology and Therapeutics at Kampala's esteemed Makerere University, one of the best medical schools in Africa.

9 months

Charity information


Moxafrica logo
  • Need


    Moxafrica, as a charity, is committed to investigating whether small cone direct moxibustion (moxa), a traditional East Asian non-pharmaceutical treatment used in the past in Japan to treat TB, might be applicable today in resource poor environments with high rates of HIV co-infection and growing levels of drug resistance which are untreatable because of lack of resource. The results from completed feasability studies strongly indicate that moxa can be effective in an African environment


    If we can prove its efficacy, we may be able to offer a solution to:
    1. increasing incidence of TB in Africa, because moxa may hasten normal first line treatment response thus reducing infectivity
    2. decrease the growth of drug-resistance by improving drug compliance by reducing their side effects
    3. help HIV co-infected patinets to respond to treatment
    4. Possibly provide the only effective help for drug resistant cases who currently have no access to diagnostics or second line drugs.

  • Aims

    Aim 1

    To establish what the cure rates are for co-infected patients on first line TB drugs plus moxa


    » Carry our a nine month study (Phase II RCT) with Makerere University monitoring 60 patients including blood tests, sputum analyses, x-rays etc

    Success will be measured by a change in the infectious status of the disease, if blood counts improve (full blood counts including CD4), or if other vital signs improve.

    Aim 2

    Eestablishi if moxa plus standard first line treatment improves life quality and reduces morbidity


    » Monitoring patients and analysing response by interviews using the Karnofsky scoring method

    Success will be measured by the Karnofsky score rising back to normal (90% and above), or by Karnofsky score rising by at least 20% above what it was at the start of treatment.

  • Impact


    The potential long term changes which could arise from successful results from this study will involve widespread dissemination of the treatment protocol across the most resource poor countries in Africa. Thr first step will be publication in international medical journals followed by advocacy with organistaions in the front line of TB treatment in Africa (MSF, Partners in Health, Merlin etc)


    Throughout the study all subjects (including those who have discontinued for any reason) will be reviewed regularly so that in case of any adverse events, action is taken almost immediately to correct/treat the complications.
    In case of any complications or if new diseases are diagnosed in the patient, investigations will be carried out to help in their complete recovery where possible.
    Any patient who develops a condition that renders them unsuitable for moxa treatment, will withdrawn.


    All donors to Moxafrica already receive regular newsletters by email. This will continue.

  • Budget

    Budget - Project Cost: £30,000

    Loading graph....
      Amount Heading Description
      £3,500 staff dedicated doctor, nurse and assistant
      £4,000 cd4 counts HIV status
      £4,500 full blood counts to assess immune status
      £4,000 liver fnct tests regular
      £4,000 renal fnctn tests regular
      £1,500 sputum analyses to assess infectivity
      £2,000 x-rays when necessary
      £4,500 transport & admin ongoing
      £2,000 contingency unforeseen circumstances
  • Background


    Kiswa Health Centre, Bugolobi, Kampala.
    This is one of the maion health centres serving Kampala and has been the location of Moxafrica's iniotial feasability study which ran from March 2010 to May 2011.


    There is an estmiated 800,000,000 poeple living in Sub-Saharan Afgrica (2007). Of these 80% are latently infected with TB (WHO) and only 1% have access to appropriate diagnostics and drugs to effectively treat DR-TB. Rates of HIV co-infection vary between countries but are estimated to be as high as 75% in some countries (WHO). Rates of drug resistance are unknown but known to be rising, and incidence of TB has risen 5 fold in fifteen years.

  • Why Us?

    Why Us?

    Moxafrica is the only charity or organisation worldwide currently investigating this treatment option

    Read more about the Charity running this project.


    Professor Paul Waako (MBChB) MSc. PhD

    Research expert Head of Department Pharmacology and Therapeutics, Makerere University Medical School

    Worodria William MBchB. Mmed PhD

    TB expert - Department of Medicines, Makerere University College of Health sciences

    Dr. Ibanda Hood MBChB

    member of faculty Department of pharmacology and therapeutics, Makerere University College of health sciences

    Jenny Craig BSc, PhD, LicAc, MBAcC

    Co-founder of Moxafrica and expert on small cone moxibustion